ZIM Laboratories Limited (ZIM LABS), a research-driven pharmaceutical company, in partnership with Neuraxpharm Group, a European specialty pharmaceutical company, has received Marketing Authorization (MA) for “Buprenorphine Sublingual Film” in Europe. This significant milestone reflects a collaborative effort to address opioid drug dependence through innovative drug delivery systems.
The Buprenorphine Sublingual Film, developed using ZIM LABS’ proprietary oral thin-film technology, dissolves rapidly under the tongue, offering faster therapeutic action and enhanced patient compliance. Its advanced formulation aims to minimize misuse, respiratory depression, and overdose risks, thereby setting new safety benchmarks in opioid dependency treatment.
The European market for Buprenorphine-based treatments surpassed USD 355 million in 2023, highlighting the increasing demand for effective solutions. ZIM LABS’ Chairman & Managing Director, Dr. Anwar Daud, emphasized that this achievement underscores the company’s commitment to advancing healthcare solutions and patient safety.
This authorization follows a co-development agreement between ZIM LABS and Neuraxpharm established in 2019. Both companies are optimistic about the product’s commercialization in the European market, furthering their mission to enhance patient outcomes through innovation.
